COMP <GO>
NXL vs NDRA // EV/EBITDA & P/E VALUATION
Nexalin Technology Inc. (NASDAQ) VS. ENDRA Life Sciences Inc. (NASDAQ) • 15-METRIC TALLY: NXL 1
— NDRA 2
■ METRIC PARITY
LAST: $1.63 (0.00%) • MKT CAP: $1.9M
valuation
—
LAST: $4.88 (+2.95%) • MKT CAP: $7.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NXL VS. NDRA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NXL | NDRA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 78.80% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | NXL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 26.2 | 42.0 | -15.87 | NDRA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.9M | $7.3M | -$5.4M | NDRA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NXL REV | NDRA REV | NXL GROSS % | NDRA GROSS % | NXL FCF | NDRA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $301.6K | $0 | 79.7% | — | -$5.0M | -$5.2M |
| FY 2024 | $168.7K | $0 | 78.3% | — | -$3.9M | -$7.4M |
| FY 2023 | $110.7K | $0 | — | — | -$3.8M | -$9.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NXL // BETA —
NDRA // BETA —